伊力替康联合顺铂与拓扑替康二线治疗小细胞肺癌疗效比较
摘要
小细胞肺癌（small cell lung cancer,SCLC）是一种高侵袭性肿瘤,生长迅速,早期即可发生远处转移,预后差。目前报道,局限期SCLC的中位生存时间（median survival time,MST）为18-20个月,广泛期SCLC的MST只有8-12个月[1];局限期SCLC的5年生存率为15%-25%,广泛期SCLC的5年生存率〈5%[2]。
出处
《山西医药杂志》
CAS
2016年第15期1793-1794,共2页
Shanxi Medical Journal
参考文献7
-
1Kurup A,Hanna NH.Treatment of small-cell lung cancer[J].Crit Rev Oncol Hematol,2004,52(2):117-126.
-
2Cheng S,Evans WK,Stys-Norman D,et al.Chemotherapy for relapsed small cell lung cancer:a systematic review and practice guideline[J].J Thorac Oncol,2007,2(4):348-354.
-
3Eckardt JR,Von Pawel J,Pujol JL,et al.PhaseⅢstudy of oraI compared with intravenous topotecan as second-line therapy in small-cell lung cancer[J].J Clin Oncol,2007,25(15):2086-2092.
-
4Zhou Y,Gwadry FG,Reinhold W C.et al.Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage:microarray analysis of dose-and time-dependent effects[J].Cancer Res,2002,62(6):1688-1695.
-
5Lara PN Jr,Natale R,Crowley J,et al.PhaseⅢtrial of irinotecan/cisplatin compared with etoposide/cisplatin in extensivestage small-cell lung cancer:clinical and pharmaco-genomic results from SWOG S0124[J].J Clin Oncol,2009,20,27(15):2530-2535.
-
6Ardizzoni A,Hansen H,Dombernowsky P,et al.Topotecan.a new active drug in the second-line treatment of small-cell lung cancer:aphaseⅡstudy in patients with refractory and sensitive disease.The European organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office,and the Lung Cancer Cooperative Group[J].J Clin Oncol,1997,15(5):2090-2096.
-
7Ramalingam S,Foster J,Gooding W,et al.Phase 2study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer[J].Cancer,2010,6(5):1344-1349.
-
1唐田,古善智,李国文,黄满平,黄斌,熊正平.经皮微波消融治疗鼻咽癌局限肝转移的疗效分析[J].中国癌症杂志,2016,26(11):943-946. 被引量：3
-
2周少华,黄逸轩,赵志龙,王林.小细胞肺癌的诊疗进展[J].中国肺癌杂志,2011,14(10):819-824. 被引量：3
-
3刘凌晓,姬巍,王建华,颜志平,曾昭冲,王小林.胰腺癌肝转移患者综合性介入栓塞治疗生存情况的回顾性分析[J].复旦学报（医学版）,2011,38(2):101-106. 被引量：11
-
4张蕾,郑义同,庄明,张为民.吉西他滨联合顺铂治疗晚期食管癌的临床观察[J].肿瘤,2012,32(11):925-928. 被引量：6
-
5李杰,林洪生,刘瑞,张玉人,侯炜.中医药序贯和巩固治疗模式对Ⅲ/Ⅳ期胃癌生存期影响的对比观察[J].肿瘤,2012,32(3):203-207. 被引量：9
-
6张丽楠,李屹,杨磊.非小细胞肺癌抗血管生成治疗进展[J].实用中医药杂志,2011,27(12):883-884. 被引量：3
-
7燕海姣,吴骏,孙文辉,王玮,吴昌平.大肠癌术后依据TopoI检测个体化治疗与传统治疗的疗效比较[J].现代肿瘤医学,2014,22(11):2629-2632.
-
8沈娣,杭晓声.吉非替尼治疗非小细胞肺癌优势人群的临床观察[J].实用癌症杂志,2011,26(1):60-62. 被引量：1
-
9刘凌晓,姬巍,王建华,王小林,颜志平,曾昭冲,林根来.介入治疗联合三维适形放疗治疗不能手术切除的胰腺癌患者疗效分析[J].中国癌症杂志,2011,21(1):46-51. 被引量：21
-
10陈蕾,王中华,胡夕春,王佳蕾,洪小南,李小秋,叶定伟.睾丸恶性淋巴瘤26例临床分析[J].肿瘤,2008,28(11):976-979. 被引量：4
